Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: Comparisons between metabolic parameters

Skeletal Radiology

Volumn 43, Issue 5, 2014, Pages 641-648

  Hong, Sun Pyo ^a   Lee, Seung Eun ^a   Choi, Yoon La ^a   Seo, Sung Wook ^a   Sung, Ki Sun ^a   Koo, Hong Hoe ^a   Choi, Joon Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Metabolic tumor volume; PET CT; Prognosis; Soft tissue sarcoma; Standardized uptake value

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG UPTAKE; EWING SARCOMA; FEMALE; FOLLOW UP; GLYCOLYSIS; HUMAN; HUMAN TISSUE; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MEDICAL PARAMETERS; MEDICAL RECORD REVIEW; MITOSIS; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; OVERALL SURVIVAL; PET-CT SCANNER; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL RATE; SYNOVIAL SARCOMA; TOTAL LESION GLYCOLYSIS; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR NECROSIS; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; INCIDENCE; METABOLISM; MIDDLE AGED; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; REPRODUCIBILITY; SARCOMA; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; STATISTICS; YOUNG ADULT;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; SARCOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84898853775     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-014-1832-7     Document Type: Article

References (33)

1. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14:869-77.
2. Ingmar I, Tobias W, Beate K, Torsten K. Oncological outcome and prognostic factors in the therapy of soft tissue sarcoma of the extremities. Orthop Rev (Pavia). 2012;4:e34.
3. Carneiro A, Bendahl PO, Engellau J, et al. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011;117:1279-87.
4. Sampo M, Tarkkanen M, Tukiainen E, et al. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation. Br J Cancer. 2012;106:1076-82.
5. Gustafson P, Akerman M, Alvegard TA, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer. 2003;39:1568-76.
6. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
7. Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med. 2003;28:815-20.
8. Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998;80:441-7.
9. Roberge D, Vakilian S, Alabed YZ, Turcotte RE, Freeman CR, Hickeson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma. 2012;2012:960194.
10. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg. 2000;231:380-6.
11. 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging. 2012;39:1416-24.
12. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335-41.
13. 18F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol. 2011;18:2783-9.
14. 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010;136:883-9.
15. 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115-22.
16. 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2013;35:15-22.
17. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-71.
18. 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging. 2013;40:1836-42.
19. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti III A, ed. AJCC Cancer Staging Manual. 7th edn. New York: Springer, 2010: 291-298.
20. 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol. 2009;192:745-53.
21. 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38:1191-202.
22. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol. 2007;25:571-8.
23. Meng X, Sun X, Mu D, et al. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82:960-6.
24. Rakheja R, Makis W, Tulbah R, et al. Necrosis on FDG PET/CT correlates with prognosis and mortality in Sarcomas. AJR Am J Roentgenol. 2013;201:170-7.
25. Warburg O. On the origin of cancer cells. Science. 1956;123:309-14.
26. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400-19.
27. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991;32:1508-12.
28. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996;37:257-61.
29. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998;4:1215-20.
30. Wong CY, Nunez R, Bohdiewicz P, et al. Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET. Eur J Nucl Med. 2001;28:1702-5.
31. 18F- misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med. 2012;53:1262-8.
32. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
33. Behranwala KA, A'Hern R, Omar AM, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol. 2004;11:714-9.